Patent 7304144 was granted and assigned to Immunex on December, 2007 by the United States Patent and Trademark Office.
The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.